A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin

Human Molecular Genetics

Volumn 22, Issue 19, 2013, Pages 3869-3882

  Damiano, Maria ^a,b,c   Diguet, Elsa ^a,b,c   Malgorn, Carole ^a,b   D'Aurelio, Marilena ^c   Galvan, Laurie ^a,b   Petit, Fanny ^a,b   Benhaim, Lucile ^a,b   Guillermier, Martine ^a,b   Houitte, Diane ^a,b   Dufour, Noelle ^a,b   Hantraye, Philippe ^a,b   Canals, Josep M ^d   Alberch, Jordi ^d   Delzescaux, Thierry ^a,b   Déglon, Nicole ^a,b,e   Beal, Flint M ^c   Brouillet, Emmanuel ^a,b  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b CNRS   (France)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; IRON SULFUR PROTEIN; LENTIVIRUS VECTOR; UBIQUINOL CYTOCHROME C REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; GENETIC MODEL; GENOMIC FRAGMENT; HUNTINGTON CHOREA; IN VIVO GENE TRANSFER; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STRIATE CORTEX; WESTERN BLOTTING;

ANIMALS; CELLS, CULTURED; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT COMPLEX II; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MUTANT PROTEINS; MUTATION; NERVE TISSUE PROTEINS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84888792149     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt242     Document Type: Article

References (72)

1. Damiano, M., Galvan, L., Deglon, N. and Brouillet, E. (2010) Mitochondria in Huntington's disease. Biochim. Biophys. Acta, 1802, 52-61.
2. Harper, P.S. (1991) Huntington's Disease. WB Saunders Company Ltd, London.
3. Borrell-Pages, M., Zala, D., Humbert, S. and Saudou, F. (2006) Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol. Life Sci., 63, 2642-2660.
4. Myers, R.H., Vonsattel, J.P., Stevens, T.J., Cupples, L.A., Richardson, E.P., Martin, J.B. and Bird, E.D. (1988) Clinical and neuropathologic assessment of severity in Huntington's disease. Neurology, 38, 341-347.
5. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
6. Cowan, C.M. and Raymond, L.A. (2006) Selective neuronal degeneration in Huntington's disease. Curr. Top. Dev. Biol., 75, 25-71.
7. Bossy-Wetzel, E., Petrilli, A. and Knott, A.B. (2008) Mutant huntingtin and mitochondrial dysfunction. Trends Neurosci., 31, 609-616.
8. Costa, V. and Scorrano, L. (2012) Shaping the role of mitochondria in the pathogenesis of Huntington's disease. EMBO J., 31, 1853-1864.
9. Mochel, F. and Haller, R.G. (2011) Energy deficit in Huntington disease:why it matters. J. Clin. Invest., 121, 493-499.
10. Browne, S.E. (2008) Mitochondria and Huntington's disease pathogenesis:insight from genetic and chemical models. Ann. N. Y. Acad. Sci., 1147, 358-382.
11. Panov, A.V., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2003) In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch. Biochem. Biophys., 410, 1-6.
12. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
13. Song, W., Chen, J., Petrilli, A., Liot, G., Klinglmayr, E., Zhou, Y., Poquiz, P., Tjong, J., Pouladi, M.A., Hayden, M.R. et al. (2011) Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat. Med., 17, 377-382.
14. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C.N., Tanese, N. and Krainc, D. (2006) Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell, 127, 59-69.
15. Browne, S.E., Bowling, A.C., MacGarvey, U., Baik, M.J., Berger, S.C., Muqit, M.M., Bird, E.D. and Beal, M.F. (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol., 41, 646-653.
16. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M. and Schapira, A.H. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol., 39, 385-389.
17. Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M.C., Lefort, N., Dufour, N., Saudou, F., Elalouf, J.M., Hirsch, E., Hantraye, P. et al. (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell, 17, 1652-1663.
18. Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M.C., Dufour, N., Elalouf, J.M., Krajewski, S., Hantraye, P., Deglon, N. et al. (2008) Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum. Mol. Genet., 17, 1446-1456.
19. Orr, A.L., Li, S., Wang, C.E., Li, H., Wang, J., Rong, J., Xu, X., Mastroberardino, P.G., Greenamyre, J.T. and Li, X.J. (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J. Neurosci., 28, 2783-2792.
20. Zabel, C., Mao, L., Woodman, B., Rohe, M., Wacker, M.A., Klare, Y., Koppelstatter, A., Nebrich, G., Klein, O., Grams, S. et al. (2009) A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for Huntington disease. Mol. Cell. Proteomics, 8, 720-734.
21. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
22. Schilling, G., Becher, M.W., Sharp, A.H., Jinnah, H.A., Duan, K., Kotzuk, J.A., Slunt, H.H., Ratovitski, T., Cooper, J.K., Jenkins, N.A. et al. (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum.Mol. Genet., 8, 397-407.
23. Solans, A., Zambrano, A., Rodriguez, M. and Barrientos, A. (2006) Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum. Mol. Genet., 15, 3063-3081.
24. Wang, H.Q., Xu, Y.X., Zhao, X.Y., Zhao, H., Yan, J., Sun, X.B., Guo, J.C. and Zhu, C.Q. (2009) Overexpression of F(0)F(1)-ATP synthase alpha suppresses mutant huntingtin aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun., 390, 1294-1298.
25. Ruiz, M. and Deglon, N. (2012) Viral-mediated overexpression of mutant huntingtin to model HD in various species. Neurobiol. Dis., 48, 202-211.
26. de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P. and Deglon, N. (2002) Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci., 22, 3473-3483.
27. Diguet, E., Petit, F., Escartin, C., Cambon, K., Bizat, N., Dufour, N., Hantraye, P., Deglon, N. and Brouillet, E. (2009) Normal aging modulates the neurotoxicity of mutant huntingtin. PLoS One, 4, e4637.
28. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P. et al. (2009) Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol., 65, 276-285.
29. Canals, J.M., Pineda, J.R., Torres-Peraza, J.F., Bosch, M., Martin-Ibanez, R., Munoz, M.T., Mengod, G., Ernfors, P. and Alberch, J. (2004) Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci., 24, 7727-7739.
30. Majumder, P., Raychaudhuri, S., Chattopadhyay, B. and Bhattacharyya, N.P. (2007) Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell. Mol. Neurobiol., 27, 1127-1145.
31. Seo, H., Kim, W. and Isacson, O. (2008) Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum. Mol. Genet., 17, 3144-3153.
32. Butterworth, J., Yates, C.M. and Reynolds, G.P. (1985) Distribution of phosphate-activated glutaminase, succinic dehydrogenase, pyruvate dehydrogenase and gamma-glutamyl transpeptidase in post-mortem brain from Huntington's disease and agonal cases. J. Neurol. Sci., 67, 161-171.
33. Mann, V.M., Cooper, J.M., Javoy-Agid, F., Agid, Y., Jenner, P. and Schapira, A.H. (1990) Mitochondrial function and parental sex effect in Huntington's disease. Lancet, 336, 749.
34. Brennan, W.A. Jr, Bird, E.D. and Aprille, J.R. (1985) Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem., 44, 1948-1950.
35. Stahl, W.L. and Swanson, P.D. (1974) Biochemical abnormalities in Huntington's chorea brains. Neurology, 24, 813-819.
36. Tabrizi, S.J., Cleeter, M.W., Xuereb, J., Taanman, J.W., Cooper, J.M. and Schapira, A.H. (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol., 45, 25-32.
37. Turner, C., Cooper, J.M. and Schapira, A.H. (2007) Clinical correlates of mitochondrial function in Huntington's disease muscle. Mov. Disord., 22, 1715-1721.
38. Scarpulla, R.C. (2011) Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim. Biophys. Acta, 1813, 1269-1278.
39. Scarpulla, R.C. (2011) Nucleus-encoded regulators of mitochondrial function: integration of respiratory chain expression, nutrient sensing and metabolic stress. Biochim. Biophys. Acta, 1819, 1088-1097.
40. Au, H.C. and Scheffler, I.E. (1998) Promoter analysis of the humansuccinate dehydrogenase iron-protein gene-both nuclear respiratory factors NRF-1 and NRF-2 are required. Eur. J. Biochem./FEBS, 251, 164-174.
41. Hodges, A., Strand, A.D., Aragaki, A.K., Kuhn, A., Sengstag, T., Hughes, G., Elliston, L.A., Hartog, C., Goldstein, D.R., Thu, D. et al. (2006) Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet., 15, 965-977.
42. Kuhn, A., Goldstein, D.R., Hodges, A., Strand, A.D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M.A., Sathasivam, K., Cha, J.H. et al. (2007) Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet., 16, 1845-1861.
43. Neupert, W. and Herrmann, J.M. (2007) Translocation of proteins into mitochondria. Annu. Rev. Biochem., 76, 723-749.
44. Klanner, C., Neupert, W. and Langer, T. (2000) The chaperonin-related protein Tcm62p ensures mitochondrial gene expression under heat stress. FEBS Lett., 470, 365-369.
45. Dibrov, E., Fu, S. and Lemire, B.D. (1998) The Saccharomyces cerevisiae TCM62 gene encodes a chaperone necessary for the assembly of the mitochondrial succinate dehydrogenase (complex II). J. Biol. Chem., 273, 32042-32048.
46. Ghezzi, D., Goffrini, P., Uziel, G., Horvath, R., Klopstock, T., Lochmuller, H., D'Adamo, P., Gasparini, P., Strom, T.M., Prokisch, H. et al. (2009) SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat. Genet., 41, 654-656.
47. Gonzalez-Cabo, P., Vazquez-Manrique, R.P., Garcia-Gimeno, M.A., Sanz, P. and Palau, F. (2005) Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum. Mol. Genet., 14, 2091-2098.
48. Mao, P., Ardeshiri, A., Jacks, R., Yang, S., Hurn, P.D. and Alkayed, N.J. (2007) Mitochondrial mechanism of neuroprotection by CART. Eur. J. Neurosci., 26, 624-632.
49. Cimen, H., Han, M.J., Yang, Y., Tong, Q., Koc, H. and Koc, E.C. (2010) Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. Biochemistry, 49, 304-311.
50. Finley, L.W., Haas, W., Desquiret-Dumas, V., Wallace, D.C., Procaccio, V., Gygi, S.P. and Haigis, M.C. (2011) Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activity. PloS One, 6, e23295.
51. Fu, J., Jin, J., Cichewicz, R.H., Hageman, S.A., Ellis, T.K., Xiang, L., Peng, Q., Jiang, M., Arbez, N., Hotaling, K. et al. (2012) trans-(-)-epsilon-Viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated protein kinase (AMPK), and protects cells in models of Huntington disease. J. Biol. Chem., 287, 24460-24472.
52. Wagner, G.R., Pride, P.M., Babbey, C.M. and Payne, R.M. (2012) Friedreich's ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via feedback inhibition of the SIRT3 deacetylase. Hum. Mol. Genet., 21, 2688-2697.
53. Rustin, P., Munnich, A. and Rotig, A. (2002) Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur. J. Hum. Genet., 10, 289-291.
54. Johri, A. and Beal, M.F. (2012) Antioxidants in Huntington's disease. Biochim. Biophys. Acta, 1822, 664-674.
55. Johri, A., Calingasan, N.Y., Hennessey, T.M., Sharma, A., Yang, L., Wille, E., Chandra, A. and Beal, M.F. (2012) Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 21, 1124-1137.
56. Xun, Z., Rivera-Sanchez, S., Ayala-Pena, S., Lim, J., Budworth, H., Skoda, E.M., Robbins, P.D., Niedernhofer, L.J., Wipf, P. and McMurray, C.T. (2012) Targeting of XJB-5-131 to mitochondria suppresses oxidativeDNA damage and motor decline in a mouse model of Huntington's disease. Cell Rep., 2, 1137-1142.
57. Sims, N.R. (1990) Rapid isolation of metabolically active mitochondria from rat brain and subregions using Percoll density gradient centrifugation. J. Neurochem., 55, 698-707.
58. Damiano, M., Starkov, A.A., Petri, S., Kipiani, K., Kiaei, M., Mattiazzi, M., Flint Beal,M.and Manfredi,G. (2006) Neural mitochondrial Ca2+ capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J. Neurochem., 96, 1349-1361.
59. D'Aurelio, M., Gajewski, C.D., Lenaz, G. and Manfredi, G. (2006) Respiratory chain supercomplexes set the threshold for respiration defects in human mtDNA mutant cybrids. Hum. Mol. Genet., 15, 2157-2169.
60. Schägger, H. (ed). (2003) Membrane Protein Purification and Crystallization. Academic Press, San Diego, CA.
61. Wittig, I., Carrozzo, R., Santorelli, F.M. and Schagger, H. (2007) Functional assays in high-resolution clear native gels to quantify mitochondrial complexes in human biopsies and cell lines. Electrophoresis, 28, 3811-3820.
62. Mattiazzi, M., D'Aurelio, M., Gajewski, C.D., Martushova, K., Kiaei, M., Beal, M.F. and Manfredi, G. (2002) Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J. Biol. Chem., 277, 29626-29633.
63. Srivastava, S., Barrett, J.N. and Moraes, C.T. (2007) PGC-1alpha/beta upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations. Hum. Mol. Genet., 16, 993-1005.
64. Sambrook, J. (ed). (1989) Molecular Cloning. Cold Spring Harbor Lab Press Plainview, New York.
65. Bell, E.L., Klimova, T.A., Eisenbart, J., Schumacker, P.T. and Chandel, N.S. (2007) Mitochondrial reactive oxygen species trigger hypoxia-inducible factor-dependent extension of the replicative life span during hypoxia. Mol. Cell. Biol., 27, 5737-5745.
66. Regulier, E., Pereira de Almeida, L., Sommer, B., Aebischer, P. and Deglon, N. (2002) Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum. Gene Ther., 13, 1981-1990.
67. Hottinger, A.F., Azzouz, M., Deglon, N., Aebischer, P. and Zurn, A.D. (2000) Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J. Neurosci., 20, 5587-5593.
68. Wong-Riley,M.(1979) Changes in the visual system of monocularly sutured or enucleated cats demonstrable with cytochrome oxidase histochemistry. Brain Res., 171, 11-28.
69. Bizat, N., Hermel, J.M., Boyer, F., Jacquard, C., Creminon, C., Ouary, S., Escartin, C., Hantraye, P., Kajewski, S. and Brouillet, E. (2003) Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J. Neurosci., 23, 5020-5030.
70. Brouillet, E., Guyot, M.C., Mittoux, V., Altairac, S., Conde, F., Palfi, S. and Hantraye, P. (1998) Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem., 70, 794-805.
71. Ackrell, B.A., Kearney, E.B. and Singer, T.P. (1978) Mammalian succinate dehydrogenase. Methods Enzymol., 53, 466-483.
72. Dubois, A., Dauguet, J., Herard, A.S., Besret, L., Duchesnay, E., Frouin, V., Hantraye, P., Bonvento, G. and Delzescaux, T. (2007) Automated three-dimensional analysis of histological and autoradiographic rat brain sections: application to an activation study. J. Cereb. Blood Flow Metab., 27, 1742-1755.